Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GAA | P10253 | 3/20 | 0.47 |
| ▸ | CYP2C9 | P11712 | 2/20 | 0.47 |
| ▸ | CYP2C19 | P33261 | 2/20 | 0.47 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.47 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.45 |
| ▸ | RECQL | P46063 | 1/20 | 0.45 |
| ▸ | ALKBH3 | Q96Q83 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | HTT | P42858 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23400217 | 0.77 | GAA (0.38) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23401810 | 0.74 | GAA (0.36) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23402202 | 0.74 | ALDH1A1 (0.42) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23401440 | 0.74 | GAA (0.39) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23400083 | 0.71 | GAA (0.34) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23401209 | 0.71 | KDM4E (0.43) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23400038 | 0.70 | GAA (0.33) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23398561 | 0.70 | GAA (0.40) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23398911 | 0.70 | GAA (0.40) | GAACYP2C9CYP2C19ALDH1A1MEN1 | |
| SCHEMBL23401526 | 0.69 | GAA (0.49) | GAACYP2C9CYP2C19ALDH1A1MEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3828159-A1 | STORAGE AND TRANSPORT STABILIZERS FOR POLYMERIZABLE COMPOUNDS | BASF SE (DE) | 2021-06-02 | — | — | EP | disclosed |
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | SEATTLE GENETICS, INC. | 2017-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170000897-A1 | MONOMETHYLVALINE COMPOUNDS CAPABLE OF CONJUGATION TO LIGANDS | MMAB, CAD, VIM | GAA 2736/4885CYP2C9 1211/4885CYP2C19 1414/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.